$113.14
1.53% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Vaxcyte Inc Stock price

$113.14
+34.36 43.62% 1M
+44.64 65.17% 6M
+50.34 80.16% YTD
+61.73 120.07% 1Y
+86.96 332.16% 3Y
+86.99 332.66% 5Y
+86.99 332.66% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+1.70 1.53%
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Key metrics

Market capitalization $13.57b
Enterprise Value $12.15b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 6.20
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-502.16m
Free Cash Flow (TTM) Free Cash Flow $-582.34m
Cash position $1.45b
EPS (TTM) EPS $-4.76
P/E forward negative
Short interest 10.64%
Show more

Is Vaxcyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Vaxcyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Vaxcyte Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Vaxcyte Inc forecast:

Buy
100%

Financial data from Vaxcyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 12 12
28% 28%
-
-12 -12
28% 28%
-
- Selling and Administrative Expenses 51 51
60% 60%
-
- Research and Development Expense 428 428
86% 86%
-
-490 -490
81% 81%
-
- Depreciation and Amortization 12 12
28% 28%
-
EBIT (Operating Income) EBIT -502 -502
79% 79%
-
Net Profit -497 -497
88% 88%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vaxcyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxcyte Inc Stock News

Neutral
GlobeNewsWire
16 days ago
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. E...
Positive
Seeking Alpha
19 days ago
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning...
Neutral
GlobeNewsWire
21 days ago
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per sha...
More Vaxcyte Inc News

Company Profile

Vaxcyte, Inc., a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is headquartered in Foster City, California.

Head office United States
CEO Grant Pickering
Employees 254
Founded 2013
Website www.vaxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today